miRTarBase - #MIRT002337


—
pre-miRNA Information
pre-miRNA mmu-mir-200c   
Genomic Coordinates chr6: 124718322 - 124718390
Description Mus musculus miR-200c stem-loop
Comment Mouse mir-200c is predicted .
RNA Secondary Structure

Mature miRNA Information
Mature miRNA mmu-miR-200c-3p
Sequence 45| UAAUACUGCCGGGUAAUGAUGGA |67
Evidence Experimental
Experiments Cloned
Putative Targets

Biomarker Information
Biomarker ID Name Type Discovered From Mode Level Source Testing Methods
B0Q8FA miR-200c Safety Biomarker (SAF) Clinical/Experimental Data Expression Higher Urine Quantitative polymerase chain reaction
Gene Information
Gene Symbol Zeb2   
Synonyms 9130203F04Rik, D130016B08Rik, SIP1, Zfhx1b, Zfx1b, Zfxh1b
Description zinc finger E-box binding homeobox 2
Transcript NM_015753   
Expression
Putative miRNA Targets on Zeb2
3'UTR of Zeb2
(miRNA target sites are highlighted)		 
>Zeb2|NM_015753|3'UTR
   1 ACTACTGCATTTTAAGCTTCCTATTTTTTTTTTCCAGTAGTATTGTTACCTGCTTGAAAACACTGCTGTGTTAAGCTGTT
  81 CATGCACGTGCCTGACGCTTCCAGGAAGCTGTAGAGAGGGACAGAAGGGGCAGTTCAGCCAAGACAGAGTTAGATGGAGT
 161 TGGATATTGTTTAAAAAAAAAAAAACTGCATTATGCAAAAATTTTGTACAGTGTTAAGGCCTAAAAACTGTGTGGTTCAG
 241 AGACTAATTCCTGTGTTTAATAGCATTTATACTTTAAGCACAACTAGAAAATTCTAAGAATTGCACTCTACGTATGTATC
 321 ACTACAAACTTAAAAAAAATTATGTCTAATTTATATTAATACATTTTAAAAGGTGCCCGCACTACCATACATCAGTATTT
 401 TATTATTATTATTATTGTTATTCCTGTTTAATTTAATGTGCCCGCACTACAGTGCATCAGTATTACGATTCCTCAACACT
 481 TTCCTTTCGCTATTCATGAATTTCCCATTGTTTTACAGCCTAAGTAACCACACACTTTTAGGCCTCAATTTTTTATTTTT
 561 TATTTTTTTCTGTGAAGGAACTTGAAGTGATGCATGTGTGAATTTAAGATACCGAAGTCTTAAAGTGACCTGGATGTGAA
 641 GGAAAAAGTAAGATGAGAAGTAAAGAAAGCCTTTGTAAGGTGGTTTTAAAAGCCTTATGCAAACCTTTTAATCTGTGTCT
 721 CTGCAAGTGCCATCCTTGTACAGTGTTCAGAGGGTAACGAGGGTTACCTTTGCACCAGCTTCAGTGTTAAGCTCACCGTG
 801 TTCTTTGAAGCACCCGTGTCAGTATTAGACGACTAGGCAGCAGTTCCTTAGTTTACATATGTTTGTGCAATTATTTTCTG
 881 TACTTTTTTGTTCATTAATTTTGTCAGTATTACACCAAACTTTTTTTGCAACAAAAAAAAATTTTTTTTTGCATTCATTT
 961 AATTTTAGGTCAAATAACATTTTATTTATGTGGCTCATTTTATATTTCCTAATTTTATTTATTTCATACTGTAGTGTACA
1041 GTATTATAGTTCTTCAATATATAGATATATTTTAGTAAAAAAGGAACATGACGTTGATCATTTGGGCAAATTTTACGTAA
1121 AGAGAAGAGCATTTATTGTGTTTTGGAACATTAATTGTGAGATGGGATTTTTCAATTTTATTATTTTATTTTTGTTTTTG
1201 TTTTTCCAATTACTGGAGATTCCAAATTTGGAAACTTTTGATACAATCTTGTGAAAACACTGTATTTTCGACTGAAAATT
1281 CCACTTTCTTCATCTTGTTTTTTAGCTAACCTCAAGAGGGACTGTTAAATACAATGTATGATACCATGACAAAAATCTTT
1361 CCTGAATTGTCTTTGTAAAAGTATTATTGAATTTTCAATTTGTAATTTCTTTTGAAAATGACCATGCTCGAATAAAAATG
1441 TAGCCAAACTAAGAATGTAGTTAATGAGTTCTGTACTTTTAGAGAGCTTTCCTTCAATGACCATTAACATGTAACATGCT
1521 TATGCTTATAATAATGCTAATTATGTTTTTCAATATAATTTTAGTTTAGCAATAATTTTGACTGGTACCAATAACTGTTT
1601 TTTAAAATTCCATACTTATGTACAGCAATTTTACAGCTTTTCTCAACTGATCCTGATTCCAGATTGTGTATTTTTTATGT
1681 GAGGTTATATTATTCAAATTTAGTCTATTTACTTTACAGACATTTCTACTTTTGCATTACAAGTATTTAGAGATTATGTG
1761 TTAAAAACTCACTTTTCTGTCCAAGGGGTCTTTGTGATTTATTCAGAAAAGTCTAATTTCAAAAAGACAGCTATTATTCA
1841 ATGTTATTTATAATATGTAACTTTTTTTCTAAGAGTTGGGATAATTTATCTCACTTTTTGAAATGCAGACTGTAGCTTAT
1921 CCTTTATCTAAGATTATAAAATGGGGGGTGGGTGGGAAAACAAAGCTAAAGGCACATGCTAACAAAAATAACCTTCATTT
2001 TCCAAGACAGTCTTTCAGTTTTTACAAGACGACCCTAATAGTCAGTATATGAATGTATTCATAGGTTTTTACACAATGAT
2081 TTTTTTTATCAGAAACCAGATTCTAATTCCTAAATCTAATAACAAAGTCAGAATAATAATACAAAAGCAGATTACCTTAT
2161 GAAATTTACAGCTCTTGAATATACGTAACTATAATATAGTAGCTGTCCACATATTTTTTCTACTTTAGAATCAAAAAACA
2241 AAAGCATGATTTTGCTATTGAATTTGCTAAAACTTTAAGTGTGACACCTCAAGTTGGCAAGAAAAACATATTTTTATTAT
2321 TTAGCCATTTTCCTAAATTTCATAAACATTGTTCCTTGAAATGACACACACACACACACACACACACACACACACACATA
2401 CATGCCCCAAGAGAGAGAAAAGATGTAATGACTATACAGAGGCAATTGAGCAGATACTTGTAGAAAGCATATTTTCAGCT
2481 CTATCTTCAAGCCTGGTGAGGACTGGCATTAGGAGAGATGGCATAAAGCATTCTGCTCCTGTCATCGCTATACCAGAGTT
2561 TGCATGTTTGGAAAGTTTACAGCATTCTTTCCCTATTTCTCCTTCTTTCAATGGCACAAATAAATACACTACATAGAAAT
2641 TTTCCCGATTTTAAAGGCTCTAGGCGATATCTTTATTAATTCAACCTGAAAATATCAAGCCATTAAATTTTGTCTGGGTA
2721 GAATAAATCCCTGTGGCCTCCTTTAAAGCAATGTAGGTCTCTGCTGCCCATGGGGCATATCTGTGTCCCTACCCACAAGA
2801 GACAGGACCAACAAAGAACACATGAGCAACATACTCTTTCTCCCCAGAAAGAAGAAAGCATGCATGAGAAGGAGCAAAGG
2881 GGAGCACAGAGTCTCCCTCCCCTCCTGAAATCCCTCTTTCCACCATTGTTTTTACAAATTACTTTTCACAGGAAGGCTCA
2961 GAATACCTGAGTCTGCAAGGATCAGGTTAACACTTGTAAATTGTGACAATCACTACAATGTCCTATATCTTAAGGTTTCT
3041 TTCCTTTTTAAAAATGCAATTTAGCCACTAATAGTATTGCACATTAGAGCTGCATAATCTTCCAACTCCAGGGAAGACTA
3121 AAACATTGGACTTATCCTAGGATTCCTTTCCAAGGTCATAAACAAGAAAGCCCTCCAAATCATGACACATAATCTCCTTT
3201 TCTTATCGAATACTCTTCCCTTGTTCTAGTCTTAAGTATTACCCTTTACCCCTGAGGATAGGGGCTGGGAAAAGGTGATG
3281 AAATCCTGGAACTGAACACCCCGCCCATTTTCTCAAGAGCCTTTTGTATTCTAGCAGATCTGGGAGGTTCTTTCTTTTTT
3361 GCACATGACACTGTAGGCTTAGTTCTGAGAAACTGGGCAAGAGAGATGAGATTTCTCAGCCAGAACTAACAGCGTTCATC
3441 TCCCTTAGCATGAACTTGAGCTTGCAGTGGAGTGGGAGGGCCTGAAGGAGGAAGGAGAGAAGGGACTATATTTGAATAGG
3521 TATTAATAAATTTATTAGATACTTTTCACAATCAGATAACTTTAAAATGTTATTTTTTATCTTCTAAGGACATAAGCCTT
3601 AACAACATCAAAATTTAGTCATAAATTTGAAGATATTCCCCAATAATAAGTTTATATATATACATATATATATATTTGAA
3681 ATAAAAAATTGTTAGCCATGTTTTTTTGCTCCAGGATGTGTGGCCATGCCAGGCTGTGAGCCCTGGATATGCACACAAAC
3761 AAGTGTGTGTGCTCTGAAGCCCCCGCACATTGTAATAAACACAGCTGCATTTATTTGAGTATGTGTTCCCGTGTACATGT
3841 AAAAACATCCAAACAAACACACTCAGCAGATTTATTTCATGTGCAATGGGGCAATTATTCAAATAAATATGCTCAATACA
3921 ATTATTTGAGTCTCGCATTTGCATGCTCATCACTCACAGAACTAATACTAAAAGAGGGGGAAACACCAAAGAATTTACGT
4001 GGGGGAAAATATATGTGAAAGCAATGTTATTGTAGATGTTATAAGGTAGCCAAAGCTATGGCTCCCTTCTTAACTGAAAC
4081 ACAATGATTTTGTATTCAGTGGCATTTGTTTCTAACGATGAATAGTTATTTCACTCACTTGATCATTACATCAGAAGGAC
4161 TGCAGTGTTTAGATTCATATAATAGCAAACTTTAAGGACCTGAAGCAGATAAGGATGAGACATCTCTATATTTCAAAAGC
4241 AGAATAGTTCTTTCTACATACTTTACATCAAAGGAACACTGATAAATTATTATGGCTCACATACGTAACTATAAATTTAA
4321 AATGTTATACATATAGAAAAACATTCCTACATTTTAAAACATTAAAAAGTCACAGATGACTCGTGTGATCATTTTATATA
4401 TTAATAAATACTACAATATATATGTGAACACATTACAAATCATATTGGTGAACAAAGAGGCTGTAAAGCCTCTCTTCAGT
4481 ATACTGACATAACCTAATATACTAAAATGGGAAGGGGCTTTTAGTCACTGAATATGCATCGTGAAACAAAGATGAAGAAA
4561 CTACATGGCTTGTGCCCATCACGAAAAAGATTCATACTGAAGGCTTAGCTTTGGTTTTTATTCAATTAAATTGTCAAACT
4641 GTGCACAGTGAACTTTTTTTTTTTTTTAGAACTTGAGACATTTGTGATGTTGGCTGTTTAAATCTTTGTTACCTTCGCTG
4721 TGAATTGAAATTGTACATATTTAGTAAATCATGCAAACAAAACAAACTTTTTAGACAATATTTTTATTGGAGAGTTTTCT
4801 TTTCCTGTATCCATGTTTAAAAAAAAAAGACCTCCTTTCCCAAAATAAAAAATGTCAATACTAAATTTAAAGAAGTATAA
4881 AGGAATAATTGCTTCCTTTAGAGCAAATATTTAAATAAACATGGAGAGAATTGGCAACATGTTCTTTTGGGGCTAATAGG
4961 CTGTGTTCAATTTTTTGGGTTAAAGTTCCAGAGGGCCTCTGTTTCACATTCAAAGATAATATATTAATCTCTGAATTAAA
5041 GAAATGCTCTTAGGTAACAGG
Target sites Provided by authors   Predicted by miRanda    DRVs    SNPs    DRVs & SNPs
miRNA-target interactions
(Predicted by miRanda)
ID Duplex structure Position Score MFE
1 
miRNA  3' agguAGUAAU--GGGCCGUCAUAAu 5'
              ||||||  :::| ||||||| 
Target 5' ttgtTCATTAATTTTGTCAGTATTa 3'
 888 - 912 165.00 -14.40
2 
miRNA  3' agguAGUAA-----UGGGC-C-GUCAUAAu 5'
              || ||     ||||| | ||||||| 
Target 5' gtgtTCTTTGAAGCACCCGTGTCAGTATTa 3'
 798 - 827 155.00 -16.40
3 
miRNA  3' agguaGUAAUGG---GCCGUCAUAAu 5'
               || ||||   |  ||||||| 
Target 5' gcccgCACTACCATACATCAGTATTt 3'
 375 - 400 154.00 -13.90
Experimental Support 1 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions HCT116
Location of target site 3'UTR
Tools used in this research TargetRank , TargetScan
Original Description (Extracted from the article) ... miR-200 was found to directly target the mRNA of the E-cadherin transcriptional repressors ZEB1 (TCF8/ EF1) and ZEB2 (SMAD-interacting protein 1 [SIP1]/ZFXH1B) ...

- Park SM; Gaur AB; Lengyel E; Peter ME, 2008, Genes & development.

Article - Park SM; Gaur AB; Lengyel E; Peter ME
- Genes & development, 2008
Cancer progression has similarities with the process of epithelial-to-mesenchymal transition (EMT) found during embryonic development, during which cells down-regulate E-cadherin and up-regulate Vimentin expression. By evaluating the expression of 207 microRNAs (miRNAs) in the 60 cell lines of the drug screening panel maintained by the Nation Cancer Institute, we identified the miR-200 miRNA family as an extraordinary marker for cells that express E-cadherin but lack expression of Vimentin. These findings were extended to primary ovarian cancer specimens. miR-200 was found to directly target the mRNA of the E-cadherin transcriptional repressors ZEB1 (TCF8/deltaEF1) and ZEB2 (SMAD-interacting protein 1 [SIP1]/ZFXH1B). Ectopic expression of miR-200 caused up-regulation of E-cadherin in cancer cell lines and reduced their motility. Conversely, inhibition of miR-200 reduced E-cadherin expression, increased expression of Vimentin, and induced EMT. Our data identify miR-200 as a powerful marker and determining factor of the epithelial phenotype of cancer cells.
LinkOut: [PMID: 18381893]
Experimental Support 2 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
     
Conditions 4TO7
Location of target site 3'UTR
Tools used in this research TargetScan
Original Description (Extracted from the article) ... "Co-transfection of the reporter plasmid with miR-200b and/or 200c in the 4TO7 cells significantly reduced luciferase expression ( ...

- Dykxhoorn DM; Wu Y; Xie H; Yu F; Lal A; et al., 2009, PloS one.

Article - Dykxhoorn DM; Wu Y; Xie H; Yu F; Lal A; et al.
- PloS one, 2009
BACKGROUND: The development of metastases involves the dissociation of cells from the primary tumor to penetrate the basement membrane, invade and then exit the vasculature to seed, and colonize distant tissues. The last step, establishment of macroscopic tumors at distant sites, is the least well understood. Four isogenic mouse breast cancer cell lines (67NR, 168FARN, 4TO7, and 4T1) that differ in their ability to metastasize when implanted into the mammary fat pad are used to model the steps of metastasis. Only 4T1 forms macroscopic lung and liver metastases. Because some miRNAs are dysregulated in cancer and affect cellular transformation, tumor formation, and metastasis, we examined whether changes in miRNA expression might explain the differences in metastasis of these cells. METHODOLOGY/PRINCIPAL FINDINGS: miRNA expression was analyzed by miRNA microarray and quantitative RT-PCR in isogenic mouse breast cancer cells with distinct metastatic capabilities. 4T1 cells that form macroscopic metastases had elevated expression of miR-200 family miRNAs compared to related cells that invade distant tissues, but are unable to colonize. Moreover, over-expressing miR-200 in 4TO7 cells enabled them to metastasize to lung and liver. These findings are surprising since the miR-200 family was previously shown to promote epithelial characteristics by inhibiting the transcriptional repressor Zeb2 and thereby enhancing E-cadherin expression. We confirmed these findings in these cells. The most metastatic 4T1 cells acquired epithelial properties (high expression of E-cadherin and cytokeratin-18) compared to the less metastatic cells. CONCLUSIONS/SIGNIFICANCE: Expression of miR-200, which promotes a mesenchymal to epithelial cell transition (MET) by inhibiting Zeb2 expression, unexpectedly enhances macroscopic metastases in mouse breast cancer cell lines. These results suggest that for some tumors, tumor colonization at metastatic sites might be enhanced by MET. Therefore the epithelial nature of a tumor does not predict metastatic outcome.
LinkOut: [PMID: 19787069]
Experimental Support 3 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Article - Oba S; Kumano S; Suzuki E; Nishimatsu H; et al.
- PloS one, 2010
Members of the miR-200 family of micro RNAs (miRNAs) have been shown to inhibit epithelial-mesenchymal transition (EMT). EMT of tubular epithelial cells is the mechanism by which renal fibroblasts are generated. Here we show that miR-200 family members inhibit transforming growth factor-beta (TGF-beta)-induced EMT of tubular cells. Unilateral ureter obstruction (UUO) is a common model of EMT of tubular cells and subsequent tubulointerstitial fibrosis. In order to examine the role of miR-200 family members in tubulointerstitial fibrosis, their expression was investigated in the kidneys of UUO mice. The expression of miR-200 family miRNAs was increased in a time-dependent manner, with induction of miR-200b most pronounced. To clarify the effect of miR-200b on tubulointerstitial fibrosis, we injected miR-200b precursor intravenously. A single injection of 0.5 nM miR-200b precursor was sufficient to inhibit the increase of collagen types I, III and fibronectin in obstructed kidneys, and amelioration of fibrosis was confirmed by observation of the kidneys with Azan staining. miR-200 family members have been previously shown to inhibit EMT by reducing the expression of ZEB-1 and ZEB-2 which are known repressors of E-cadherin. We demonstrated that expression of ZEB-1 and ZEB-2 was increased after ureter obstruction and that administration of the miR-200b precursor reversed this effect. In summary, these results indicate that miR-200 family is up-regulated after ureter obstruction, miR-200b being strongly induced, and that miR-200b ameliorates tubulointerstitial fibrosis in obstructed kidneys. We suggest that members of the miR-200 family, and miR-200b specifically, might constitute novel therapeutic targets in kidney disease.
LinkOut: [PMID: 21049046]
Experimental Support 4 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
     
Conditions NIH 3T3
Location of target site 3'UTR
Tools used in this research miRanda
Original Description (Extracted from the article) ... "Pre-miR芒鈥灺 Precursor Molecules for these 51 miRNAs were co-transfected into NIH3T3 cells with a luciferase reporter vector containing the 3芒鈧虏UTR region of the Zeb-2 mRNA. Seven miRNAs (miR-141 ...

- Oba S; Mizutani T; Suzuki E; Nishimatsu H; et al., 2013, BMC research notes.

miRNA-target interactions (Provided by authors)
ID Duplex structure Position
1 
miRNA  3' agguAGUAA-----UGGGC-C-GUCAUAAu 5'
              || ||     ||||| | ||||||| 
Target 5' gtgtTCTTTGAAGCACCCGTGTCAGTATTa 3'
 		1 - 30
Article - Oba S; Mizutani T; Suzuki E; Nishimatsu H; et al.
- BMC research notes, 2013
BACKGROUND: Although identification of the target mRNAs of micro RNAs (miRNAs) is essential to understanding their function, the low complementarity between miRNAs and their target mRNAs has complicated this process. In this study, we sought to identify miRNAs which reduce the expression of the transcription factor Zeb-2, a transcriptional repressor of E-cadherin which is known to be down regulated by members of the miR-200 family (miR-200a,b,c miR-429, and miR-141). FINDINGS: We first used a computational target predicting system to identify 82 candidate miRNAs which bound the 3'UTR region of the Zeb-2 mRNA. Of these 82 miRNAs, precursors for 51 were available in our miRNA precursor library. Pre-miR Precursor Molecules for these 51 miRNAs were co-transfected into NIH3T3 cells with a luciferase reporter vector containing the 3'UTR region of the Zeb-2 mRNA. Seven miRNAs (miR-141, mi-183, miR-200a, miR-200b, miR-200c, miR-429 and miR-666-5p) were shown to down-regulate luciferase activity and Western blotting analysis confirmed that Pre-miR Precursor Molecules for these seven miRNAs induced expression of E-cadherin and miScript target protector against miR-183 and miR-666-5p abrogated this effect. Moreover, an Anti-miR miRNA Inhibitor targeting miR-183 and miR-666-5p repressed expression of E-cadherin. CONCLUSIONS: We have established a method to identify miRNAs that bind the 3'UTR region of the Zeb-2 mRNA and that induce expression of E-cadherin, possibly by down-regulating the expression of Zeb-2. Our method may be more widely applicable for identifying miRNAs that bind target mRNA 3'UTR regions and down-regulate the expression of proteins encoded by these mRNAs.
LinkOut: [PMID: 24245745]
33 mmu-miR-200c-3p Target Genes:
Functional analysis:
ID Target Description Validation methods
Strong evidence Less strong evidence
MIRT002336 Zeb1 zinc finger E-box binding homeobox 1 4 3
MIRT002337 Zeb2 zinc finger E-box binding homeobox 2 3 4
MIRT005946 Flt1 FMS-like tyrosine kinase 1 1 1
MIRT006426 Mapk14 mitogen-activated protein kinase 14 2 1
MIRT009810 ZEB1 zinc finger E-box binding homeobox 1 1 1
MIRT009811 ZEB2 zinc finger E-box binding homeobox 2 1 1
MIRT053235 Sox2 SRY (sex determining region Y)-box 2 4 1
MIRT418784 Map2 microtubule-associated protein 2 1 1
MIRT438019 Bmi1 Bmi1 polycomb ring finger oncogene 2 1
MIRT438582 Zfpm2 zinc finger protein, multitype 2 2 1
MIRT438658 Nog noggin 5 1
MIRT577097 Fhod1 formin homology 2 domain containing 1 1 3
MIRT577625 St3gal2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 1 1
MIRT578593 Hist1h1d histone cluster 1, H1d 1 4
MIRT579059 Cradd CASP2 and RIPK1 domain containing adaptor with death domain 1 1
MIRT581140 Senp5 SUMO/sentrin specific peptidase 5 1 2
MIRT581298 Rnf166 ring finger protein 166 1 1
MIRT581364 Rdh10 retinol dehydrogenase 10 (all-trans) 1 1
MIRT581743 Plxnc1 plexin C1 1 1
MIRT581831 Pkib protein kinase inhibitor beta, cAMP dependent, testis specific 1 1
MIRT582081 Ogfod1 2-oxoglutarate and iron-dependent oxygenase domain containing 1 1 2
MIRT582414 Mphosph9 M-phase phosphoprotein 9 1 2
MIRT582457 Mgat3 mannoside acetylglucosaminyltransferase 3 1 1
MIRT582940 Ikzf5 IKAROS family zinc finger 5 1 1
MIRT583984 Ddx26b integrator complex subunit 6 like 1 1
MIRT595499 Mtf2 metal response element binding transcription factor 2 1 1
MIRT595530 Foxn3 forkhead box N3 1 1
MIRT596310 Rassf10 Ras association (RalGDS/AF-6) domain family (N-terminal) member 10 1 1
MIRT596609 Zfp459 zinc finger protein 459 1 1
MIRT601132 Bri3bp Bri3 binding protein 1 1
MIRT603385 Sh2d4a SH2 domain containing 4A 1 1
MIRT731202 Reln reelin 2 1
MIRT756395 Cd274 CD274 antigen 1 1
miRNA-Drug Associations
miRNA Small Melocule FDA CID Detection Method Condition PMID Year Expression Pattern of miRNA
miR-200c All-trans-retinoic acid (ATRA) approved 444796 Quantitative real-time PCR breast cancer cells 23904188 2013 up-regualted
miR-200c Glucose NULL 5793 Microarray endothelial cells 24394957 2014 up-regulated
miR-200c Hydroxamic acid HDACi LAQ824 NULL NULL Microarray breast cancer cell line SKBr3 16452179 2006 up-regulated
miR-200c Trichostatin A (TSA) NULL 444732 Microarray human pancreatic cancer cell line BxPC-3 19112422 2009 up-regulated
miR-200c Trichostatin A (TSA) NULL 444732 Northern blot human pancreatic cancer cell line BxPC-3 19112422 2009 up-regulated
miR-200c 17beta-estradiol (E2) approved 5757 Microarray MCF-7 breast cancer cells 19528081 2009 up-regulated
miR-200c Activin A NULL 229455 Quantitative real-time PCR Human embryonic stem (hES) cells 19885849 2010 up-regulated
miR-200c 5-Fluorouracil approved 3385 Microarray HCT-8 colon cancer cell line 19956872 2010 down-regulated
miR-200c CDF(analogues of curcumin) NULL NULL Quantitative real-time PCR pancreatic cancer (gemcitabine-sensitive) BxPC-3 cells and gemcitabine-resistant MIAPaCa-E (relatively resistant to gemcitabine) and MIAPaCa-M (highly resistant to gemcitabine) 20388782 2010 up-regulated
miR-200c CDF(analogues of curcumin) + gemcitabine NULL NULL Quantitative real-time PCR pancreatic cancer (gemcitabine-sensitive) BxPC-3 cells and gemcitabine-resistant MIAPaCa-E (relatively resistant to gemcitabine) and MIAPaCa-M (highly resistant to gemcitabine) 20388782 2010 up-regulated
miR-200c 5-Fluorouracil approved 3385 Microarray MCF-7 breast cancer cells 21506117 2011 up-regulated
miR-200c 1,3-bis(2 chloroethyl)-1-nitrosourea (BCNU) NULL 2578 Quantitative real-time PCR Human umbilical vein endothelial cells 21527937 2011 up-regulated
miR-200c Hydrogen peroxide (H2O2) NULL 784 Quantitative real-time PCR Human umbilical vein endothelial cells 21527937 2011 up-regulated
miR-200c DNA methyltransferases (DNMTs) + 5-azacytidine (5-AzaC) NULL NULL Quantitative real-time PCR umbilical cord blood-derived multipotent stem cells(hUCB-MSCs) 21572997 2011 up-regulated
miR-200c Arsenic trioxide approved 14888 Quantitative real-time PCR acute promyelocytic leukemia 22072212 2012 up-regulated
miR-200c Metformin approved 4091 Quantitative real-time PCR pancreatic cancer cells 22086681 2012 up-regulated
miR-200c Metformin approved 4091 Quantitative real-time PCR pancreatic cancer cells 22086681 2012 up-regulated
miR-200c CDF(analogues of curcumin) NULL NULL Quantitative real-time PCR pancreatic cancer cells 22108826 2012 up-regulated
miR-200c Marine fungal metabolite 1386A NULL NULL Microarray MCF-7 breast cancer cells. 22159329 2012 up-regulated
miR-200c Paclitaxel + Cyclopamine NULL NULL Quantitative real-time PCR prostate cancer cell 22768203 2012 up-regulated
miR-200c Catechin approved 9064 Microarray apoE−/− mice 22253797 2012 up-regulated
miR-200c Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) NULL 8490 Microarray mouse brain 19270793 2009 down-regulated
miR-200c Tert-butyl hydroperoxide (t-BHP) NULL 6410 Microarray mouse auditory cells 20510889 2010 up-regulated
miR-200c Reversine NULL 210332 Microarray C2C12 myoblast cells 24513286 2014 up-regulated
miR-200c Dexamethasone approved 5743 Microarray adrenals and granulosa cells 24205079 2014 down-regulated
miR-200c Perfluorooctane sulfonate NULL 74483 Microarray zebrafish embryos 20878907 2011 up-regulated
miR-200c Curcumin NULL 969516 Quantitative real-time PCR Y79 RB cells. 22510010 2012 up-regulated
miR-200c Furan NULL 8029 Quantitative real-time PCR liver 22079235 2011 up-regulated
miRNA-Drug Resistance Associations
miRNA Drug Name CID NSC FDA Effect/Pattern Detection Method Level Phenotype Condition
mmu-miR-200c-3p Paclitaxel 36314 NSC125973 approved sensitive Low Ovarian Cancer tissue and cell line (HeyTGL)
mmu-miR-200c-3p Docetaxel 148124 NSC628503 approved sensitive Low Gastric Cancer tissue and cell line (BGC-823)
mmu-miR-200c-3p Erlotinib 176870 NSC718781 approved resistant Low Non-Small Cell Lung Cancer tissue and cell line (PC-9, ErlR)
mmu-miR-200c-3p Trastuzumab sensitive Low Breast Cancer tissue and cell line (SKBR3)

Error report submission